LP-01
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →
Ionizable lipid for LNP and nucleic-acid delivery research.
Genevant CL1 (lipid 10) is a novel ionizable lipid for rna delivery.Lipid 10 rapidly accumulated in the liver within the first hour of dosing (reflecting LNP uptake), but levels then steadily declined over the ensuing 2 weeks period, similar to MC3.Lipid 10 afforded more than double the expression of either approved lipid. We also observed high splenic expression for ALC-0315, which correlated with higher MCP-1 levels.Animals received a single 5 µg IM dose of LNP encapsulating firefly luciferase (fLuc) mRNA. Whole body imaging was performed 6 h later and expression at the injection site quantified. Lipid 10, ALC-0315, and SM-102 showed similar expression at the injection site, all greater than the older generation benchmarks lipids (DLinDMA, KC2, MC3). Lipid 10 and ALC-0315 also showed high expression in the liver, while SM-102 was less, and more similar to MC3.Lipid 10-based LNP reported similar anti-HA IgG titers to MC3 and ALC-0315 (Comirnaty) LNP, and higher than the SM-102 (SpikeVax) LNP composition. MCP-1 levels were generally similar, although the ALC-0315 composition had a significantly higher response at the 5 µg dose. All formulations reported good stability when stored frozen at −80 °C or at 2–8 °C for 1 month.
| CAS No. | Not available |
| Chemical Name | Genevant CL1 (lipid 10) |
| Synonyms | Lipid CL1,Genevant CL 1, Genevant CL-1 |
| SMILES | C(C(CCC/C=C\CCCCC)CCC/C=C\CCCCC)(OC(CCCCN(C)C)=O)CCC/C=C\CCCCC |
| Formula | C39H73NO2 |
| M.Wt | 588.00 |
| Purity | ELSD-HPLC>95% |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid-Nanoparticle Components for Therapeutic and Vaccine Applications Kieu Lam, Ada Leung, Alan Martin, Mark Wood, Petra Schreiner, Lorne Palmer, Owen Daly, Wenchen Zhao, Kevin McClintock, James Heye-- 21 January 2023 https://doi.org/10.1002/adma.202209624 |
The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.
Solvent volumes update from the molecular weight above.
| Mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 17.0068 mL | 3.4014 mL | 1.7007 mL |
| 25 mg | 42.5170 mL | 8.5034 mL | 4.2517 mL |
| 50 mg | 85.0340 mL | 17.0068 mL | 8.5034 mL |
| 100 mg | 170.0680 mL | 34.0136 mL | 17.0068 mL |
| 250 mg | 425.1701 mL | 85.0340 mL | 42.5170 mL |
Contact our team with the catalog number and requested quantity.